Genelux Corporation
corporate_fare Company Profile
Genelux Corporation (NASDAQ:GNLX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for GNLX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for GNLX spans 10-Q, DEF 14A, 424B5, 8-K.
Recent high-impact activity:
- Q3 Loss Widens to $10.29M, Missing Consensus by $1.5M as Phase 3 Costs Climb
- Genelux Q3 Loss Widens to $10.3M; Going Concern Reaffirmed, Runway Into Q1 2027
- Olvi-Vec Case Report Shows 16.7-Month PFS in Platinum-Relapsed SCLC
- Genelux Q2 Loss Widens to $9.5M; Phase 3 Ovarian Cancer Data Due 2H26
- Genelux Q2 Loss Widens to $9.5M; Cash Runway Into Q1 2027
Financial Snapshot
Short Interest & Short Volume
8.32 days to coverFINRA reported short interest of 4,530,210 shares in GNLX as of the October 30, 2026 settlement, a 2.4% decrease from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 58.7% of GNLX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.